FeesSafety
Pluang+

UC Davis activated as clinical trial site for CERo's Phase 1 study of CER-1236 in blood cancers

Others
27 Oct 2026, 00:21 WIB
GlobeNewsWire
View Source
Bullish
UC Davis activated as clinical trial site for CERo's Phase 1 study of CER-1236 in blood cancers

CERo Therapeutics has activated the University of California, Davis as a clinical trial site for its ongoing Phase 1 CERTAIN-T trial testing CER-1236 in patients with hematologic malignancies. UC Davis will also serve as the primary manufacturing site, which is expected to streamline treatment logistics and expand patient recruitment. Early trial results show a favorable safety profile with no severe adverse events and some preliminary clinical improvements. The study now includes additional blood cancers like MDS and myelofibrosis, with ongoing assessments of safety and efficacy.

CERo Therapeutics' clinical trial site activation news comes as Inovio Pharmaceuticals Inc (INO) leads gains in the health sector with an 87% buy order activity on Pluang. For readers following health-sector US stocks, here is Pluang's market snapshot as of Oct 27, 2026 04:12 WIB: out of 150 priced stocks, 81 rose and 69 fell. Summit Therapeutics Inc (SMMT) declined by 6.08%, and Smith & Nephew plc (SNN) rose 5.54% with 100% sell order activity.

More News

Presidio named Global Innovation Partner of the Year at Cisco Partner Summit 2026

Presidio named Global Innovation Partner of the Year at Cisco Partner Summit 2026

At the Cisco Partner Summit 2026, Presidio was honored as the Global Innovation Partner of the Year, recognizing its outstanding innovation and success in delivering impactful customer solutions. This award highlights Presidio's commitment to partner...

Market News
Bullish
1 hour ago
Presidio named Global Services and Software Excellence Partner of the Year at Cisco Partner Summit 2026

Presidio named Global Services and Software Excellence Partner of the Year at Cisco Partner Summit 2026

Presidio was awarded the Global Services and Software Excellence Partner of the Year at the Cisco Partner Summit 2026. This award recognizes Presidio's outstanding innovation and success in delivering solutions that help customers achieve meaningful ...

Market News
Bullish
1 hour ago
Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...

Market News
Bullish
3 hours ago
Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...

Company Fundamentals
Neutral
3 hours ago
S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App